Herbert H. Loong

机构：Chinese University of Hong Kong, Prince of Wales Hospital, Dana-Farber Cancer Institute · ORCID：0000-0002-6607-1106

发表论文 328 篇 · 总被引 9190 次 · h-index 42

代表论文

• Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer (2025 · New England Journal of Medicine · 被引 53)
• Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer (2025 · Cancer Discovery · 被引 18)
• Pattern of failure, impact of local therapy, and characteristics of long-term responders with advanced EGFR mutation positive non-small cell lung cancer treated with first-line osimertinib (2025 · Lung Cancer · 被引 3)
• Exploring the "sweet spot": in vitro efficacy of tumor treating fields and potential for synergy with cytotoxic therapy in bone and soft tissue sarcomas (2026 · Research Square)
• Lung cancer across borders: From molecular epidemiology to precision treatment strategies (2026 · Therapeutic Advances in Medical Oncology)
• Consensus recommendations for the management of Dato-DXd-associated adverse events in patients with advanced/metastatic NSCLC: insights from a multiregional steering committee (2026 · Therapeutic Advances in Medical Oncology)